Menu Back toTOPIC-2-SESSION-4-The-Role-of-the-Qualified-Person-Responsible-for-Pharmacovigilance

Joint MHRA/DIA Excellence in Pharmacovigilance

This course is designed to provide a firm grounding in key aspects of European Clinical Pre- and Post-Marketing Safety regulatory requirements.


TOPIC 2 SESSION 4: The Role of the Qualified Person Responsible for Pharmacovigilance

Session Chair(s)

Gaby L. Danan, MD, PhD

Gaby L. Danan, MD, PhD

  • Pharmacovigilance Expert
  • GLD, France
Phil  Tregunno

Phil Tregunno

  • Group Manager, Vigilance, Intelligence and Research Group
  • Medicines and Healthcare Products Regulatory Agency (MHRA), United Kingdom

Speaker(s)

Vicki  Edwards

The Role of the Qualified Person Responsible for Pharmacovigilance

Vicki Edwards

  • Vice President, Pharmacovigilance Excellence and International QPPV
  • AbbVie, Inc., United Kingdom
Margaret Anne Walters

The Role of the Qualified Person Responsible for Pharmacovigilance

Margaret Anne Walters

  • Deputy EU Qualified Person for Pharmacovigilance
  • Merck, Sharp & Dohme Ltd, United Kingdom

Contact us


Registration Questions

Send Email
+41 61 225 51 51



Agenda and Logistics

Send Email
+41 61 225 51 55